Term
| Patenting of human disease genes |
|
Definition
| Promise offered by the BROCA test in terms of improving womens reproductive health care may be limited by patents by Myriad Genetics |
|
|
Term
|
Definition
| Myriad Genetics holds patents for BRCA1 and BRCA2 in some other countries, including four patents obtained from the european patent office. |
|
|
Term
|
Definition
| If a woman is recommended to get a full sequencing of her BRCA genes she must have it done through Myriad Genetics using Sanger Sequencing of the two target cells. |
|
|
Term
|
Definition
| Patent protections may enable Myriad Genetics to block the use of the BROCA test in clinical settings since it uses the BRCA1 and BRCA2 genes. |
|
|
Term
| Patents in the human genome |
|
Definition
By 2010 there were US patents on an estimated 20% of genes in the human genome including many disease genes.
Patents cover both the DNA sequences and the methods |
|
|
Term
|
Definition
With rapid advances in genomics and allied fields, knowledge of the genetic foundations of health and disease is increasing exponentially, while the costs of genomic analyses are decresing substantially.
Thus, the new genomic technologies offer great clinical potential for improving health care |
|
|
Term
|
Definition
| Patent laws appear to be impeding this clinical potential. Instead of convering only comercial applications, patent cover the pure forms of the genes, thus control the basics of research. |
|
|
Term
| Lawsuit against Myriad Genetics |
|
Definition
In may 2009 the association for molecuar pathology filed suit against Myriad stating that their patents are not constitutional.
Judge ruled that DNA was not marked differentlu from a product of nature. |
|
|
Term
|
Definition
| Myriad genetics appealed the lawsuit, but the US department of justice ruled that the "BRCA genes, their deleterious alleles, and their relationship to breast cancer are the products of evolution, not human invention" |
|
|
Term
|
Definition
In July of 2011 the uS court of Appeals for the federal circuit reversed the ruling and concluded that isolated DNA is eligible for patents.
Supreme court agreed in November of 2012. |
|
|
Term
| Obtainig a wealth of personal genetic information |
|
Definition
| Clinical implementation of conprehensive NGS-based diagnostic testing for ovarian and related cancers, for recessive childhood diseases and for other heritable diseases means that individuals will have the option of obtaining a wealth of personal genetic information. |
|
|
Term
| Discriminatory use in health insurance and employment |
|
Definition
| Genes will be used in the health insurance rule. |
|
|
